|One Franklin Pkwy , San Mateo, CA 94403|
|Fund Manager||Team Managed|
Maximize total return, consistent with prudent investment management and liquidity needs, by investing to obtain the average duration specified below. The fund invests in a portfolio of fixed income securities of various maturities and, under normal market conditions, will invest at least 80% of its net assets in debt and fixed income securities. Although the fund may invest in debt and fixed income securities of any maturity, under normal market conditions the target dollar-weighted average effective duration for the fund, as estimated by the fund s subadviser, is expected to range within 20%of the duration of its benchmark, the Bloomberg Barclays Intermediate U.S. Government/Credit Index. Effective duration seeks to measure the expected sensitivity of market price to changes in interest rates, taking into account the anticipated effects of particular features of a security (for example, some bonds can be prepaid by the issuer).
|Asset Type||% Of Allocation|
|Total Net Assets||2.76 M|
|Criteria||3 Years||5 Years||10 Years|
|Minimum Initial IRA||$250|
|Timeframe||Average Annual Current Performance Monthly As Of 09/30/2021||Average Annual Current Performance Quarterly As Of 09/30/2021||Avg Annual Current Performance Monthly As Of 09/30/2021||Avg Annual Current Performance Quarterly As Of 09/30/2021|
|Life Of Fund||
Master The Market with the Help of Our Financial Experts
Philip Morris posts a third-quarter earnings beat as sales of its smokeless non-tobacco products continue strong, though cautions on supply chain impact.
Travelers Companies posts third-quarter earnings that exceed analysts’ forecasts as a drop in what it calls ‘catastrophic losses’ offsets record net written premiums.
Solid third quarters continue to power stocks higher Tuesday, even as growth and inflation signals remain stubbornly persistent as oil prices top $85 a barrel in overnight trading.
Procter & Gamble held its 2022 forecasts in place, seeing sales growth of between 2% and 4%, following stronger-than-expected first quarter earnings.
Johnson & Johnson said it sees 2021 vaccine sales of $2.5 billion, with overall revenues rising to between $94.1 billion to $94.6 billion, following its Q3 earnings beat.
Stocks edge higher ahead of earnings; SEC says GameStop surge powered by believers; FDA set to approve "mix & match' COVID boosters; DraftKings faces Entain bid deadline and Rent the Runway seeks $1.3 billion valuation in Nasdaq IPO.